GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Raia Drogasil SA (OTCPK:RADLY) » Definitions » Beginning Cash Position

Raia Drogasil (Raia Drogasil) Beginning Cash Position : $83 Mil (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Raia Drogasil Beginning Cash Position?

Raia Drogasil's Beginning Cash Position for the quarter that ended in Mar. 2024 was $83 Mil.

Raia Drogasil's quarterly Beginning Cash Position increased from Sep. 2023 ($70 Mil) to Dec. 2023 ($121 Mil) but then declined from Dec. 2023 ($121 Mil) to Mar. 2024 ($83 Mil).

Raia Drogasil's annual Beginning Cash Position declined from Dec. 2021 ($156 Mil) to Dec. 2022 ($68 Mil) but then increased from Dec. 2022 ($68 Mil) to Dec. 2023 ($88 Mil).


Raia Drogasil Beginning Cash Position Historical Data

The historical data trend for Raia Drogasil's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Raia Drogasil Beginning Cash Position Chart

Raia Drogasil Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 58.86 58.16 155.68 67.89 88.48

Raia Drogasil Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 83.24 76.49 69.92 121.15 82.80

Raia Drogasil Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.


Raia Drogasil Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Raia Drogasil's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.


Raia Drogasil (Raia Drogasil) Business Description

Traded in Other Exchanges
Address
Avenue Corifeu de Azevedo Marques, 3097 Butanta, Sao Paulo, SP, BRA, 05339-9000
Raia Drogasil SA is a large retail drug store operator in Brazil. The company's stores sell branded and generic medication, over-the-counter medicine, health and beauty aids, perfumery, cosmetics, household items, and personal care products. The company also acts as a pharmacy benefit manager, performing medical purchases with prenegotiated discounts. The majority of Raia Drogasil's revenue is generated through branded drug sales, while the bulk of the remaining revenue stems from perfumery, over-the-counter drugs, and generic drugs. The company owns a variety of stakes in operational subsidiaries.

Raia Drogasil (Raia Drogasil) Headlines

From GuruFocus

Q2 2023 Raia Drogasil SA Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q2 2019 Raia Drogasil SA Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q1 2019 Raia Drogasil SA Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q3 2019 Raia Drogasil SA Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q4 2019 Raia Drogasil SA Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q4 2022 Raia Drogasil SA Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q3 2021 Raia Drogasil SA Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q3 2022 Raia Drogasil SA Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q1 2021 Raia Drogasil SA Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q1 2022 Raia Drogasil SA Earnings Call Transcript

By GuruFocus Research 02-14-2024